clinical trial · NCT03462719
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Janssen Research & Development, LLC·phase3·active not recruiting·n = 211
Leukemia, Lymphocytic, Chronic, B-CellIbrutinibVenetoclaxChlorambucilObinutuzumabIbrutinib (as Subsequent Therapy)
brief summary
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
started
Apr 17, 2018
primary completion
Feb 26, 2021
completion
Apr 5, 2029
last updated
Apr 13, 2026
official title
A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol